» Articles » PMID: 24491908

Tardive Dyskinesia in Relation to Estimated Dopamine D2 Receptor Occupancy in Patients with Schizophrenia: Analysis of the CATIE Data

Overview
Journal Schizophr Res
Specialty Psychiatry
Date 2014 Feb 5
PMID 24491908
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective of this study was to evaluate the relationship between antipsychotic-induced tardive dyskinesia (TD) and estimated dopamine D2 receptor occupancy levels in patients with schizophrenia, using the dataset from the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE).

Methods: The dataset from 218 subjects (risperidone, N=78; olanzapine, N=100; ziprasidone, N=40) who presented with a score of zero on the Abnormal Involuntary Movement Scale (AIMS) at baseline in Phase 1 of the CATIE study, and remained for ≥6months, was used. Peak and trough dopamine D2 receptor occupancy levels on the day of the AIMS assessment at the endpoint were estimated from plasma antipsychotic concentrations, using population pharmacokinetic analysis and our D2 prediction model. The estimated dopamine D2 receptor occupancy levels were compared between patients who presented an AIMS score of ≥2 at endpoint and those with a score of zero, using the Mann-Whitney U test.

Results: Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07). When the analyses were separately conducted for the three drugs, there were no significant differences in estimated peak or trough D2 occupancy although the values were consistently numerically higher among those developing involuntary movements.

Conclusion: Greater dopamine D2 receptor blockade with antipsychotics at trough might increase the risk of tardive involuntary movements although this finding needs to be replicated in larger trials.

Citing Articles

Treatment of severe tardive dyskinesia with concurrent administration of olanzapine, clonazepam, baclofen, and gabapentin: a case report.

Guo X, Chen J, Wang W, Jiang B, Liang B J Int Med Res. 2023; 51(10):3000605231195154.

PMID: 37812512 PMC: 10563481. DOI: 10.1177/03000605231195154.


Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.

Abe Y, Yagishita S, Sano H, Sugiura Y, Dantsuji M, Suzuki T Cell Rep Med. 2023; 4(10):101208.

PMID: 37774703 PMC: 10591040. DOI: 10.1016/j.xcrm.2023.101208.


Improvement of Tardive Dyskinesia during Mindfulness Meditation.

Santoro M, English I, Sezer I, Amagat M, Ly F, Chaneac E Neurol Int. 2021; 13(3):439-444.

PMID: 34564288 PMC: 8482190. DOI: 10.3390/neurolint13030043.


Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.

Noordsy D, Glynn S, Sugar C, OKeefe C, Marder S J Psychiatr Res. 2017; 95:299-307.

PMID: 28942217 PMC: 5653420. DOI: 10.1016/j.jpsychires.2017.09.008.


Classics in Chemical Neuroscience: Aripiprazole.

Casey A, Canal C ACS Chem Neurosci. 2017; 8(6):1135-1146.

PMID: 28368577 PMC: 5495458. DOI: 10.1021/acschemneuro.7b00087.


References
1.
Kontny N, Wurthwein G, Joachim B, Boddy A, Krischke M, Fuhr U . Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Cancer Chemother Pharmacol. 2013; 71(3):749-63. DOI: 10.1007/s00280-013-2069-1. View

2.
Stroup T, McEvoy J, Swartz M, Byerly M, Glick I, Canive J . The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003; 29(1):15-31. DOI: 10.1093/oxfordjournals.schbul.a006986. View

3.
Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo D . Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011; 31(3):318-25. DOI: 10.1097/JCP.0b013e318218d339. View

4.
Turrone P, Remington G, Kapur S, Nobrega J . Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005; 57(4):406-11. DOI: 10.1016/j.biopsych.2004.10.023. View

5.
Uchida H, Mamo D, Pollock B, Suzuki T, Tsunoda K, Watanabe K . Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Ther Drug Monit. 2012; 34(2):182-7. DOI: 10.1097/FTD.0b013e3182489a6f. View